Compare Nebius Group NV (NBIS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs Neurocrine Biosciences Inc — how do they compare? Nebius Group NV trades at $211.25 (market cap $49.06B), while Neurocrine Biosciences Inc trades at $156.86 (market cap $16.46B). The key difference: Nebius Group NV is far larger — about 3× Neurocrine Biosciences Inc's market cap, and Nebius Group NV is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIS | NBIX | |
|---|---|---|
Market Cap | $49.06B | $16.46B |
Sector | Technology | Health |
52-Week High | $286.69 | $185.50 |
52-Week Low | $64.06 | $123.10 |
Enterprise Value | $49.26B | $16.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
